- Status:
- Red
- Decision Date:
- July 2022
Comments
RED:
- NICE TA799 - Faricimab for treating diabetic macular
oedema. ICB commissioned.
- NICE TA800 - Faricimab for treating wet age-related
macular degeneration. ICB commissioned
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again
